CLINICAL TRIALS PROFILE FOR VOSPIRE ER
✉ Email this page to a colleague
All Clinical Trials for Vospire Er
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00550550 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) | Completed | ALK-Abelló A/S | Phase 3 | 2007-11-01 | The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma. |
NCT00550550 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-11-01 | The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma. |
NCT00562159 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) | Completed | ALK-Abelló A/S | Phase 3 | 2007-11-01 | This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet. |
NCT00562159 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-11-01 | This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet. |
NCT00649779 ↗ | Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-09-01 | The objective of this study was to investigate the bioequivalence of Mylan's albuterol sulfate extended-release 8 mg tablets to Pliva's VoSpire™ ER 8 mg tablets following a single, oral 8 mg (1 x 8 mg) dose administered under fasting conditions. |
NCT00649987 ↗ | Fed Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2005-09-01 | The objective of this study was to investigate the bioequivalence of Mylan's albuterol sulfate extended-release 8 mg tablets to Pliva's VoSpire™ ER 8 mg tablets following a single, oral 8 mg (1 x 8 mg) dose administered under fed conditions. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Vospire Er
Condition Name
Clinical Trial Locations for Vospire Er
Trials by Country
Clinical Trial Progress for Vospire Er
Clinical Trial Phase
Clinical Trial Sponsors for Vospire Er
Sponsor Name